<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813305</url>
  </required_header>
  <id_info>
    <org_study_id>CSTC1-01</org_study_id>
    <nct_id>NCT01813305</nct_id>
  </id_info>
  <brief_title>CSTC1 for Diabetic Foot Ulcers Phase II Study</brief_title>
  <official_title>A Randomized,Double-Blind,Vehicle-controlled,Parallel,Phase II Study to Evaluate Efficacy and Safety of CSTC1 in Patient With Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charsire Biotechnology Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ASKLEP Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charsire Biotechnology Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of CSTC1 in patient with
      diabetic foot ulcers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of complete ulcer closure during up to 12 weeks of treatment period</measure>
    <time_frame>12 weeks</time_frame>
    <description>Complete ulcer closure is defined as 100% skin re-epithelialization without drainage or dressing requirements confirmed at two consecutive study visits 2 weeks apart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The ulcer closure time</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the time to complete ulcer closure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The half ulcer closure time (CT50)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the time to half ulcer closure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ulcer closure rate</measure>
    <time_frame>Weeks 1, 2, 3, 4, 6, 8, 10, 12</time_frame>
    <description>The proportion of ulcer closure at each post-treatment visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ulcer size</measure>
    <time_frame>Baseline, weeks 1, 2, 3, 4, 6, 8, 10, 12</time_frame>
    <description>The ulcer size at each post-treatment visit minus the ulcer size at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in ulcer size for each post-treatment visit</measure>
    <time_frame>Baseline, weeks 1, 2, 3, 4, 6, 8, 10, 12</time_frame>
    <description>Calculated as (Ulcer size at post treatment visit - Ulcer size at baseline)/(Ulcer size at baseline)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse event incidence</measure>
    <time_frame>Weeks 1, 2, 3, 4, 6, 8, 10, 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in physical examination results</measure>
    <time_frame>Baseline, weeks 1, 2, 3, 4, 6, 8, 10, 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Net change from baseline in laboratory test results</measure>
    <time_frame>Baseline, weeks 1, 2, 3, 4, 6, 8, 10, 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Net change from baseline in vital signs</measure>
    <time_frame>Baseline, weeks 1, 2, 3, 4, 6, 8, 10, 12</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Wounds</condition>
  <arm_group>
    <arm_group_label>CSTC1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CSTC1 (vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof), topical, two times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSTC1 Matched vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched vehicle, topical, two times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSTC1</intervention_name>
    <description>vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof</description>
    <arm_group_label>CSTC1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSTC1 Matched vehicle</intervention_name>
    <arm_group_label>CSTC1 Matched vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  With either gender aged at least 20 years old;

          -  With a diabetic ulcer (which is defined as the target ulcer) on the foot and not
             healing for at least 2 weeks;

          -  The target ulcer is classified as grade 1 or 2 ulcer according to modified Wagner
             system;

          -  The target ulcer should show &quot;infection control&quot; at investigator's discretion;

          -  Subject should be free of any necrosis or infection in soft and bone tissue;

          -  Subject has signed the written informed consent form

        Exclusion Criteria:

          -  With active osteomyelitis;

          -  With target ulcer size decreased by at least 50% after at least 2 weeks of
             standard-of-care-only period or any other recorded regular therapy before
             Randomization visit;

          -  With poor nutritional status (albumin &lt; 3g/dl), poor diabetic control (HbA1c &gt; 12%),
             anemia (hemoglobin&lt;10 g/dL), a leukocyte counts &lt; 1,000/mm3, abnormal liver function
             (AST, ALT&gt;3 x upper limit of normal range);

          -  Requiring treatment with corticosteroids, immunosuppressive or chemotherapeutic
             agents;

          -  Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement;

          -  Receiving revascularization surgery performed &lt;8 weeks before entry in the study;

          -  With known or suspected hypersensitivity to any ingredients of study product and
             vehicle;

          -  With coronary heart disease with myocardial infarction, coronary artery bypass graft
             (CABG), or percutaneous transluminal coronary angioplasty (PTCA) within 3 months prior
             to study;

          -  Pregnant or lactating or premenopausal with childbearing potential but not taking
             reliable contraceptive method(s) during the study period;

          -  Enrollment in any investigational drug trial within 4 weeks before entering this
             study;

          -  With any uncontrolled illness judged by the investigator that entering the trial may
             be detrimental to the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Su-Shin Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Medical University Chung-Ho Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shr-Wei Chen, MS</last_name>
    <phone>886-2-2365-0660</phone>
    <phone_ext>301</phone_ext>
    <email>douglas-chen@a2healthcare.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Su-Shin Lee, MD</last_name>
      <phone>886-7-3208176</phone>
      <email>sushin@kmu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2013</study_first_submitted>
  <study_first_submitted_qc>March 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2013</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Foot Ulcer</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Debridement</keyword>
  <keyword>Standard of Care</keyword>
  <keyword>wounds</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

